Industry experts committed to cures.
Andrew D. Ashe
Andrew brings more than 25 years of experience to his role as AGTC’s General Counsel and has extensive experience representing public companies, including multiple IPOs, follow-on financings and acquisition transactions. Most recently, he served as Executive Vice President, Administration, Corporate Secretary and General Counsel for Dyax Corp. until it was acquired by Shire Plc in 2016. During his tenure at Dyax, Andrew managed all legal, compliance and administrative functions during a period of rapid growth in which the company’s market capitalization grew from $180 million to $6 billion. While at Dyax, he also established more than 75 revenue-generating collaborations with biotech and pharma companies in the United States, Europe, India, Australia and Japan. In addition to his legal capabilities, Andrew was also responsible for transforming Dyax’s human resource department and corporate culture, resulting in the company being named to the Boston Globe Top Places to Work in 2013, 2014 and 2015.
Previously, Andrew was a member of the business law practices at Prince Lobel Tye LLP and Nutter, McClennen & Fish LLP. Prior to attending law school, he also served as a Trading Specialist and Senior Analyst of Corporate Listings for the American and New York Stock Exchanges. Andrew holds a B.A. in Finance from the Isenberg School of Management, University of Massachusetts and a J.D. from The George Washington University School of Law.
- Our Team
- Board of Directors
- Scientific Advisors
- Careers and Internships